{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-044838","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.333259+00:00","generated_at":"2026-05-22T14:11:59.621940+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nuvectis Pharma Q1 2025 net loss $5.3M; cash $29.9M; NXP900 Phase 1b advancing","bullets":["Cash and equivalents $29.9M as of Mar 31, 2025, up from $18.5M at Dec 31, 2024, driven by $14.0M net public offering proceeds.","Net loss $5.3M for Q1 2025 vs $4.2M in Q1 2024; R&D expenses $3.7M, G&A $1.9M.","NXP900 Phase 1a data at AACR showed robust pharmacodynamic response; Phase 1b enrollment in specific genetic alterations pending.","NXP800 Phase 1b study in ARID1a-mutated ovarian cancer enrolling; update expected in two months.","Completed $15.5M financing extending projected cash runway into Q1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-044838","json":"https://secwatch.observer/filing/0001104659-25-044838.json","markdown":"https://secwatch.observer/filing/0001104659-25-044838.md","text":"https://secwatch.observer/filing/0001104659-25-044838.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465925044838/0001104659-25-044838-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465925044838/tm2514104d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T14:11:59.621940+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}